Opiate Dependence Clinical Trial
Official title:
Behavioral Drug and HIV Risk Reduction Counseling With MMT in China
This study will provide critical data regarding the efficacy for reducing drug-and sex-related HIV transmission risk behaviors, as well as improving methadone maintenance treatment (MMT) outcomes and patient functioning of two transportable counseling models, behavioral drug and HIV risk reduction counseling (BDRC) and educational counseling (EC) as compared with the current standard of care model in MMT in China. Evidence-based counseling that is efficacious in reducing HIV risks and drug use and is feasible to provide with MMT will greatly improve the public health benefits of disseminating MMT in China and elsewhere in the world.
China currently has 1.2 to 3.5 million heroin users (50% with current injection drug use, IDU), and more than 650,000 HIV infected individuals, with 75,000 new infections each year and the majority of HIV infections attributable to IDU. The Chinese government recently embarked on an ambitious program to make methadone maintenance treatment (MMT) widely available to all heroin addicts. By the end of 2008, approximately 560 methadone maintenance treatment clinics had been established, providing treatment to an estimated 166,000 heroin users. However, the current methadone programs provide limited or no drug counseling, and, despite considerable initial promise, many patients continue drug use and risky behaviors while still in MMT or discontinue treatment prematurely. In addition to risky injecting practices, drug users in China also commonly engage in risky sexual practices. Most of China's drug users are young, unmarried, sexually active and only a small fraction report consistent condom use. Their knowledge about HIV/AIDS, sexually transmitted diseases and blood borne viruses is very poor. The combination of poor knowledge and frequent engagement in high-risk behaviors increases their own risk of infections, and also contributes significantly to the spread of HIV into the general population. [Consequently, we propose a randomized clinical trial to compare the efficacy of MMT combined with one of three manual-guided counseling approaches, Behavioral Drug and HIV Risk Reduction Counseling (BDRC), Educational Counseling (EC), and counseling approximating what is provided as treatment as usual (TAU) in China. Efficacy will be evaluated with regard to our primary outcome measures: reduction of drug- and sex-related HIV risk behaviors, reduction of frequency of heroin or other illicit opiate use, and duration of opiate abstinence. The study will also evaluate treatment effects on secondary outcome measures (including treatment retention, reductions in other illicit drug use, and improvements of functional status of MMT patients) and incremental resource utilization associated with BDRC, EC and TAU. In preliminary work, we have developed and pilot tested Mandarin versions of the BDRC manual, BDRC and EC training materials, and assessment instruments. Treatment seeking volunteers(N=300) entering MMT will be randomly assigned to 4 months of treatment with one of the three manual-guided treatments. A standard methadone induction and dosing protocol will be used for all subjects to ensure comparable methadone dosages in all groups. All primary and secondary outcome measures will be evaluated during the 4 months of MMT treatment phase and for 6 months following the active treatment phase. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03538444 -
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
|
N/A | |
Completed |
NCT01690546 -
Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence
|
Phase 2 | |
Completed |
NCT01389167 -
Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia
|
Phase 3 | |
Completed |
NCT01442493 -
Reengineering Methadone Treatment Study of Patient-centered Methadone Treatment
|
N/A | |
Completed |
NCT01182402 -
Electronic Compliance Monitoring in Opioid Substitution Treatment
|
N/A | |
Completed |
NCT00987961 -
Linking Hospitalized Injection Drug Users to Buprenorphine
|
Phase 3 | |
Completed |
NCT00634803 -
Clinical Trial of Integrated Treatment for Pain and Opioid Dependence
|
Phase 1/Phase 2 | |
Completed |
NCT00757744 -
Behavioral Drug and HIV Risk Reduction Counseling in Methadone Patients in China
|
Phase 3 | |
Completed |
NCT00566969 -
Cocaine Withdrawal and Pharmacotherapy Response
|
N/A | |
Completed |
NCT00577408 -
Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone
|
Phase 3 | |
Completed |
NCT00539123 -
Drug Counseling and Abstinent-Contingent Take-Home Buprenorphine in Malaysia
|
N/A | |
Recruiting |
NCT00241930 -
Integrating Buprenorphine Into HIV Treatment
|
Phase 4 | |
Completed |
NCT00218621 -
The Effects of Methadone and Buprenorphine on Fetal Neurobehavior and Infant Neonatal Abstinence Syndrome - 1
|
Phase 2 | |
Completed |
NCT00406484 -
Brief Introductory Therapy for Opioid Dependence
|
Phase 2 | |
Completed |
NCT00580827 -
Clinical Efficacy of Disulfiram in LAAM-Maintained Cocaine Abusers
|
N/A | |
Completed |
NCT03015597 -
Pilot Study of Contingency Management for Smoking Cessation
|
N/A | |
Completed |
NCT01393392 -
Developing a Smoking Cessation Intervention for Methadone Maintained Smokers
|
Phase 1 | |
Completed |
NCT01416584 -
A Bridge to Treatment: The Therapeutic Workplace and Methadone Treatment
|
N/A | |
Recruiting |
NCT00439049 -
Substance Abuse Pre-Treatment Screening Study
|
||
Withdrawn |
NCT00398008 -
HIV Risk Reduction and Drug Abuse Treatment in Iran
|
Phase 2 |